Testing LY4006896 for safety in people with Parkinson's disease
Tests the drug LY4006896 against placebo in healthy adults and people with Parkinson's.
Plain-language title generated from the registry record
Registry title: A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
Key facts
- Where
- Hachiōji and Yufu, JapanSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 85 years old?
Source: NCT06809400, who can take part
Where in Japan
- P-One ClinicHachiōji, JapanTaking people
- Oita University HospitalYufu, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06809400
- Record updated
- 14 October 2026
- Original description
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.Read full original descriptionShow less
A Single-Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Inclusion: Part A Single Ascending Dose (SAD) and B Multiple Dose (MD); Have a body mass index within the range of 18 to 34 kilogram per square meter (kg/m²) (inclusive); For Japanese participants: To qualify as a participant of first-generation Japanese origin, the participant, the participant's biological parents, and all of the participant's biological grandparents must be of exclusive Japanese descent and born in Japan; Have venous access sufficient to allow for blood sampling or administration of study intervention for IV administration, or both; Part A (SAD) Only; Participant must be 30 to 85 years of age (inclusive), at the time of signing the informed consent; Are overtly healthy; For Chinese participants: To qualify as Chinese for this study, all 4 of the participant's biological grandparents must be exclusive Chinese descent and born in China; Part B (MD) Only; Participant must be 40 to 85 years of age (inclusive), at the time of signing the informed consent; Diagnosis of Parkinson's disease per United Kingdom (UK) Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria; If presently untreated for Parkinson's disease, clinical status is not expected to require changes in symptomatic treatment within 52 weeks from baseline; If presently being treated for Parkinson's disease, receiving a stable dose of symptomatic dopaminergic therapy, including monoamine oxidase-B inhibitor, levodopa/carbidopa or dopamine agonist for at least 90 days prior to baseline and not expected to change within 52 weeks; Have a Montreal Cognitive Assessment (MoCA) score of greater than or equal to (≥) 24.
Exclusion: Are receiving continuous infusion therapy with anti-parkinsonian medications, including but not limited to subcutaneous foslevodopa-foscarbidopa, subcutaneous apomorphine, or intraduodenal/intestinal levodopa formulations; Diagnostic assessments; Have significant neurological disease affecting the central nervous system (CNS) (other than Parkinson's disease in Part B cohorts) that may affect the participant's ability to complete the study; Have a history or presence of serious or unstable illnesses or conditions that, in the investigator's opinion, could interfere with the analyses in this study, or increase risk for study intervention administration, or result in a participant's life expectancy of less than 24 months; Have known allergies to LY4006896, related compounds, or any components of the formulation, or history of allergic reactions to any transferrin receptor antibodies; Have significant allergies to humanize monoclonal antibodies; Have clinically significant multiple or severe drug allergies (including, but not limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, or exfoliative dermatitis); or intolerance to topical corticosteroids, or severe posttreatment hypersensitivity reactions; Have history or presence of uncontrolled asthma, significant autoimmune disease, hereditary angioedema, or known history of common variable immune deficiency; Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or a preexisting history of hypertension; Part B (MD) Only; Have an abnormal blood pressure or pulse rate, or both, as determined by the investigator, or have uncontrolled hypertension, defined as a systolic blood pressure greater than (>) 150 mmHg or a diastolic blood pressure >95 mmHg at Screening or Treatment Visits; Hemoglobin A1c 6.5 percent (%) or higher; Part A (SAD) and B (MD); Evidence of clinically significant anemia; Part A (SAD) Only; Have an implanted deep brain stimulation (DBS) system or any other implanted neurostimulation device (including but not limited to spinal cord stimulation, vagus nerve stimulation or investigational neuromodulation devices).